AMERICAN HEADACHE SOCIETY

Due to the COVID-19 pandemic, the 63rd American Headache Society Annual Scientific Meeting was held in a fully virtual format from June 03-06.

Due to the COVID-19 pandemic, the 62nd AHS Congress was a Virtual Congress. This site enables you to access the presentations that have been presented at the AHS virtual meeting

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

JUNE 9-12 | Hybrid

JUNE 3-6 | Virtual

JUNE 13 | Virtual

American Headache Society

View the list of presentations

Patient-reported Outcomes of Migraine Treatment With Erenumab Versus Topiramate: Results From the HER-MES Study

Reuter U.(2022). Patient-reported Outcomes of Migraine Treatment With Erenumab Versus Topiramate: Results From the HER-MES Study. Headache 62;S1,1-170. Pg.118
Published Abstract

Efficacy of erenumab in chronic migraine (CM) patients with acute headache medication overuse (MO) headache: a post hoc analysis assessing outcomes using different definitions of remission

Tepper, S.J. (2020). Efficacy of Erenumab in Chronic Migraine (CM) Patients With Acute Headache Medication Overuse (MO): A Post Hoc Analysis Assessing Outcomes Using Different Definitions of Remission. Headache, 60;S1, 1–207. Pg. 105
Published Abstract

Beyond Frequency Alone – Exploring What Meaningful Improvement Means in the Treatment of Migraine: Focus Groups in Patients and Health Care Providers

Sacco, P. (2020). Beyond Frequency Alone- Exploring What Meaningful Improvements Means in the Treatment of Migraine: Focus Groups in Patients and Health Care Providers. Headache, 60;S1, 1–207. Pg. 130
Published Abstract

Cardiovascular safety of erenumab in patients with migraine and aura

Ashina, M. (2020). Cardiovascular Safety of Erenumab in Patients with Migraine and Aura. Headache, 60;S1, 1–207. Pg. 101
Published Abstract

Benefit of migraine prevention with erenumab in patients receiving background standard-of-care acute treatment

Starling, A.J. (2020). Benefit of Migraine Prevention with Erenumab in Patients Receiv-ing Standard-of-care Acute Treatment. Headache, 60;S1, 1–207. Pg. 101
Published Abstract

Effect of erenumab on monthly migraine days and monthly migraine attacks in patients with episodic migraine

Tfelt-Hansen, P. (2020). Effect of erenumab on monthly migraine days and monthly migraine attacks in patients with episodic migraine. Headache, 60;S1, 1–207. Pg. 101
Published Abstract

Effects of erenumab on patient-reported outcomes in a subgroup of patients with episodic migraine and severe functional impairment

Lipton, R.B. (2020). Effects of Erenumab on Patient-Reported Outcomes in a Sub-group of Patients With Episodic Migraine and Severe Functional Impairment. Headache, 60;S1,1–207. Pg. 104
Published Abstract

Sustained efficacy and safety of erenumab in patients with episodic migraine who failed 2–4 prior preventive treatments: 2-year results of the LIBERTY open-label extension study

Reuter, U. (2020). Sustained Efficacy and Safety of Erenumab in Patients With Episodic Migraine Who Failed 2-4 Prior Preventive Treatments: 2-Year Interim Results of the LIBERTY Open-label Extension Study. Headache, 60;S1,1–207. Pg. 96
Published Abstract
Erenumab is co-developed by Novartis and Amgen
Cookie Settings
© Copyright 2022 Novartis Pharma AG